Ironwood Pharmaceuticals IRWD Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

Ionis PharmaceuticalsIONS

——

Other financials

Income statement

See full

Revenue$106.5M+159%

Operating income$72.6M+349%

Net income$40.8M+209%

EPS (diluted)$0.24+204%

Balance sheet

See full

Cash & equivalents$220.5M+103%

Total debt$212.4M+1,323%

Total equity-$217.1M+35.0%

Total assets$434.6M+32.8%

Cash flow

See full

Operating cash flow$5.1M-74.3%

CapEx-—

Free cash flow$74.6M+390%

Valuation

See full

Market cap$632.12M+457%

Enterprise value$624M+3,024%

P/E6.2×—

P/S1.8×+1.4×

Profitability

See full

Gross margin99.2%—

Operating margin55.4%+38.7pp

Net margin28.3%+22.3pp

FCF margin24.7%-11.1pp

Returns & leverage

See full

Return on equity29.7%-138pp

Debt / equity0×-0.5×

Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ironwood Pharmaceuticals's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?: Ironwood Pharmaceuticals (IRWD) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$106K in Q1 2026.
How has Ironwood Pharmaceuticals's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?: Ironwood Pharmaceuticals's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 1414.3% year-over-year, from -$7K to -$106K.